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Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis?
M. Drent, J.A. Jacobs, J. de Vries, R.J.S. Lamers, I.H. Liem, E.F.M. Wouters. #ERS
Journals Ltd 1999.
ABSTRACT: The aim of this study was to assess whether the cellular bronchoalveolar
lavage fluid (BALF) profile, particularly the number of polymorphonuclear neu-
trophils (PMNs), is associated with disease severity of sarcoidosis and its usefulness in
determining remission.
Twenty-six nonsmoking outpatients with sarcoidosis were included in this study.
The patients were divided into two subgroups according to the absolute number of
PMNs in BALF: #0.26104 cells.mL-1 (group 1; n=15) and >0.26104 cells.mL-1
(group 2; n=11).
The radiographic stage, high-resolution computed tomography (HRCT) findings,
67Ga lung uptake as well as lung function tests differed significantly between group 1
and 2. Follow-up revealed that 14 (93.3%) patients of group 1 compared to four
(36.4%) of group 2 recovered spontaneously without the help of corticosteroids. In
contrast, no differences were found in the number of lymphocytes in BALF nor in the
serum angiotensin converting enzyme (sACE) level between both groups. The number
of PMNs, the transfer factor of the lungs for carbon monoxide (TL,CO), the forced
expiratory volume in one second (FEV1) and one of the HRCT subscores discrimi-
nated between patients with different disease progression. Of these parameters the
PMNs appeared to be the only one which differentiated patients who demonstrated
remission and those who deteriorated.
In conclusion, these results indicate that the number of polymorphonuclear neu-
trophils in bronchoalveolar lavage fluid distinguish between sarcoidosis patients who
demonstrated remission and those having a more severe course of the disease. Whe-
ther polymorphonuclear neutrophils may be considered as markers of disease activity
and/or prognosis in sarcoidosis needs further investigation.
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Sarcoidosis is a multisystemic disease of unknown
origin, characterized by the formation of noncaseating epi-
theloid cell granulomas, probably antigen driven, and de-
rangement of normal tissue architecture [1±3]. Granuloma
formation in the lung is preceded by a mononuclear cell
alveolitis with increased numbers of activated T-lympho-
cytes and alveolar macrophages [1±6]. Studies employ-
ing bronchoalveolar lavage fluid (BALF) have resulted in
major advances in the understanding of the pathogenesis
of many pulmonary diseases. Furthermore, bronchoalve-
olar lavage (BAL) has the potential to be useful for as-
sessment of disease activity, prognosis and in guiding
therapy. In other interstitial lung disorders with various,
rather uncertain, prognoses, such as idiopathic pulmonary
fibrosis (IPF), a marked increase in polymorphonuclear
neutrophils (PMNs) and/or eosinophils was reported to
adversely affect prognosis, whereas elevated lymphocyte
counts were found to be more likely to be associated with
a good response to corticosteroid treatment [7, 8]. How-
ever, until now, there has been no consensus about the
relation of the cellular composition of BALF with clinical
features and the results of other diagnostic procedures in a
given individual sarcoidosis patient. Moreover, BALF
analysis results possess limited prognostic value. Thus,
this is the most critically discussed issue in the field of
BAL, which needs to be clarified.
The aim of the present study was to investigate whether
the BALF cellular profile, particularly the number of
PMNs, is associated with: 1) disease severity reflected by
clinical features, 2) the results of other diagnostic proced-
ures, and 3) its usefulness in determining whether treat-
ment is required or spontaneous remission is anticipated in
sarcoidosis. As smoking has been found to adversely affect
the alveolar inflammation, only nonsmoking patients suf-
fering from sarcoidosis and control subjects were evaluated.
Material and methods
Subjects
Twenty-six nonsmoking outpatients with newly sus-
pected sarcoidosis (11 females, 15 males; aged 40.811.9
yrs (meanSD)) were included in this study. The diagnosis
of sarcoidosis was based on consistent clinical features,
together with BALF analysis results [9]. Moreover, all
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patients had a biopsy confirmation of sarcoidosis. The
clinical symptoms of the respective patients varied from
none (sarcoidosis detected on routine chest radiography)
to more or less severe respiratory symptoms or erythema
nodosum and arthralgia (i.e. Lofgren's syndrome). None
of the subjects participating had any significant medical
history or comorbidity. No patient had taken corticoster-
oids prior to when the BAL was performed. Moreover,
cultures of the BALF samples obtained were all negative.
In the course of the initial diagnosis, serological para-
meters including serum angiotensin converting enzyme
(sACE) and C-reactive protein (CRP) were assessed.
To be informed about the presence of constitutional
symptoms, the patients participating completed a symptom
questionnaire [10] under supervision of a study assistant,
to ensure correct answers and to avoid omission of data.
The control group consisted of 11 nonsmoking healthy
volunteers (never smokers; zero pack-yrs), without any
pulmonary history, having normal chest radiography and
lung function tests. Written informed consent was ob-
tained from all participating subjects.
Bronchoalveolar lavage
BAL was performed as previously reported during fib-
reoptic bronchoscopy [9]. In brief, after premedication
(atropine and sometimes diazepam) and local anaesthesia
of the larynx and bronchial tree (lidocaine 0.5%), BAL
was performed by standardized washing of the middle
lobe with four aliquots of 50 mL sterile saline (0.9%
NaCl) at 378C. After careful mixing the BALF recovered
was split into two portions, kept on ice in a siliconized
specimen trap. Portion one was separated from cellular
compounds by centrifugation (for 5 min at 3506g). After
an additional centrifugation step (for 10 min at 1,0006g)
supernatants were directly stored at -708C. The cells were
washed twice, counted and suspended in minimal essen-
tial medium (MEM; Gibco, Grand Island, NY, USA)
supplemented with 1% bovine serum albumin (BSA;
Organon, Teknika, Boxtel, the Netherlands). Preparations
of the cell suspensions were made in a cytocentrifuge
(Cytospin 3, Shandon Scientific Ltd., Astmoor, UK). Cy-
tospin slides of BAL cells were stained with May-
GruÈnwald±Giemsa (MGG; Merck, Darmstadt, Germany)
for cell differentiation. At least 500 cells were counted.
Lung function and respiratory muscle strength
Lung function measurements included forced expiratory
volume in one second (FEV1), and inspiratory vital capa-
city (IVC) measured with a pneumotachograph (Masterlab,
Jaeger, WuÈrzburg, Germany). The transfer factor of the
lung for carbon monoxide (TL,CO) was measured by the
single-breath method. Values were expressed as a percen-
tage of those predicted [11].
Inspiratory and expiratory muscle strength were as-
sessed by measuring maximal respiratory mouth pressures
using the method of L.F. Black and R.E. Hyatt as pre-
viously reported [12]. Maximal inspiratory mouth pres-
sure (PI,max) was measured at residual volume (RV),
whilst maximal expiratory mouth pressure (PE,max) was
measured at total lung capacity (TLC). The equipment
used was a pressure transducer (model MP 45-30; Vali-
dyne Engineering Corp., Northridge, CA, USA). All sig-
nals were recorded on a strip chart (type BD 31; Kipp &
Zonen, Delft, the Netherlands). Values are expressed as
absolute terms and as percentage of predicted values [12].
Chest radiographs
Chest radiographs were made in the posterior±anterior
and lateral projections, and were classified by a single
experienced reader, blinded to the patients' clinical history,
in a standard manner according to the radiographic stage
(0±IV).
HRCT
Thin section scans with 1 mm collimation were obtained
at 10-mm intervals through the chest. The scanning param-
eters included 137 kVp, 255 mA, and 1-s scanning time.
Both mediastinal (width 400 HU; level 40 HU) and lung
(width 1,600 HU; level -800 HU) window images were
obtained. Scans were reconstructed with a high-frequency
reconstruction algorithm. A single experienced reader,
blinded to the patient's clinical history, classified the scans.
The typical patterns of parenchymal involvement were
qualitatively registered as thickening or irregularity of the
bronchovascular bundle (BVB), intraparenchymal nodules
(ND), septal and nonseptal lines (LS) and parenchymal
consolidation (PC; including ground-glass opafication) as
well as the volume affected, which was quantified by a
visual score: 0=no lesions found; 1=#33%; 2=#66%; 3=
$66% of the volume affected. Similarly, the quantification
of the focal pleural (PL) thickening with respect to the en-
largement of the lymph nodes (LN) was performed: 0=no
pathological findings, 1=minor, 2=moderate, and 3=pro-
nounced changes [13].
Gailium-67 scintigraphy
To objectify the extent of sarcoidosis, 67Ga scintigraphy
was performed. Planar images were obtained 48 and 96 h
after intravenous injection of 148 MBq (4 MCi) of 67Ga-
citrate, using a dual head gamma camera (Siemens Multi-
spect II, Hoffman estates, IL, USA) with medium energy
collimators [14]. A single experienced reader, blinded to
the patient's clinical history, classified the scintigrams.
Accumulation of 67Ga in the lungs, mediastinum or hilar
lymph nodes was considered pathological if the intensity
equalled or exceeded liver uptake. Active sarcoidosis
outside the thorax was also repeatedly detected, but these
findings were not evaluated extensively in this study.
Statistical analysis
The data of the control subjects and sarcoidosis patient
groups were compared using one way analyses of variance
(ANOVA) for ordinal values and Chi-squared tests for
nominal values. Differences in personal characteristics
were assessed using Chi-squared tests for nominal data and
Student's t-tests for continuous data. Results are presented
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as meanSD unless stated otherwise. In order to evaluate
the remission, one-way ANOVAs were employed. In all
tests a p-value of <0.05 was considered to be statistically
significant. All analyses were performed using the Statisti-
cal Package for Social Science (SPSS) for Windows (SPSS,
Chicago, IL, USA). In addition, Cohen's d (mean differ-
ence divided by the pooled standard deviation) was used
for effect size. A Cohen's d of $0.8 is considered a large
effect [15]. A value of $0.5 indicates a moderate effect.
The higher the Cohen's d-value is, the more relevant the
difference between two compared groups is.
Results
Bronchoalveolar lavage fluid analysis results
The sarcoidosis patient population (n=26) was divided
into two subgroups with respect to the number of PMNs.
As none of the control subjects (n=11) nor the control sub-
jects of previous studies [5, 6, 9] had an absolute number
of PMNs in BALF of >0.26104 cells.mL-1 this value was
used as cut-off value. Group 1 (n=15) consisted of pa-
tients with a normal absolute number of PMNs (#0.26104
cells.mL-1) in BALF, and group 2 (n=11) consisted of
those patients with a high number of PMNs (>0.26104
cells.mL-1). The BALF analysis results of the studied
sarcoidosis patients as well as the healthy control group
are given in table 1. The total cell count, the differential
cell counts as well as the CD4/CD8 ratio differed signifi-
cantly between both sarcoidosis subpopulations and the
control group. Between group 1 (normal absolute number
of PMNs) and group 2 (high number of PMNs) no signi-
ficant differences were found regarding the other cell
types present in BALF (table 1). Microscopic and cyto-
logical examination of the BALF samples revealed no
acid-fast bacilli, fungi or atypical cells.
Clinical characteristics of the studied sarcoidosis pa-
tients
The clinical characteristics of the sarcoidosis subgroups
1 (normal PMNs) and 2 (high PMNs) are summarized in
table 2. The time between the onset of symptoms and the
final diagnosis of sarcoidosis was 0.870.40 yrs (range 0±
6 yrs) in group 1 and 1.000.54 yrs (range 0±6 yrs) in
group 2, respectively. Of the symptoms associated with
extrapulmonary localization of the sarcoidosis only arth-
ralgia differed between both groups (group 1: 66.6%;
group 2: 18.2%; Chi-squared (l)=5.8, p<0.02). These
symptoms were treated with supportive care including
physical therapy and sometimes nonsteroidal anti-inflam-
matory drugs (NSAIDS). No differences were found in
the sACE level between group 1 and 2 nor in any other
laboratory parameter assessed. The FEV1, FVC and TL,CO
(all expressed as percentage of the predicted value)
appeared to be lower in the subgroup with a high absolute
number of PMNs in BALF (group 2; p<0.0001) as well as
the resting arterial oxygen tension (p<0.05). The radio-
graphic stage appeared to be high in group 2 compared to
group 1 (p<0.001) as well as the 67Ga uptake in the lung
parenchyma (p<0.001). Moreover, the HRCT visual scores
varied between group 1 and 2 (p<0.05; table 2). None of
the studied patients had signs of pleural thickening.
Follow-up of the studied sarcoidosis patients
The mean follow-up time for group 1 was 16 months
(range 10±28 months), and for group 2 18 months (range
9±34 months). Follow-up of the respiratory symptoms and
related clinical features revealed that 14 out of the 15
(93.3%) patients of group 1 recovered spontaneously, in
contrast to four of the 11 (36.4%) patients of group 2.
These latter four patients were found to have a radio-
graphic stage classification of II. The reason for initiating
treatment included the presence of respiratory symptoms,
particularly desaturation during exercise. This treatment
was started three months (range, 0±6 months) after the
initial BAL was performed. Initially, all of the treated pa-
tients received corticosteroids. The one treated patient out
of group 1 reported no relapse following cessation of cor-
ticosteroid therapy for >1 yr.
In two of the seven patients of group 2 who required
systemic corticosteroid treatment complete remission was
achieved. Two others of the treated patients deteriorated
after withdrawal of the corticosteroids. Therefore, the
treatment with corticosteroids was restarted and has contin-
ued until now (follow-up 18 and 24 months, respec-
tively).
Table 1. ± Bronchoalveolar lavage fluid (BALF) characteristics of patients with sarcoidosis and healthy control subjects
Group 1 Group 2 Group 3
Cohen's d
n=15 n=11 n=11 Group 1 vs 2 Group 1 vs 3 Group 2 vs 3
Yield % 55.43.6+ 41.15.2# 59.63.4 0.31 0.57 0.43
104 cells.mL-1 19.53.4# 18.73.9# 10.31.5 0.92 1.19 0.30
AM % 57.36.0# 61.24.7# 83.31.8 0.06 1.40 1.97
104 cells.mL-1 11.22.9# 11.93.2 9.31.4 0.67 0.54 0.29
Lymphocytes % 40.76.1# 30.64.5# 14.81.8 0.41 1.41 1.38
104 cells.mL-1 8.01.8# 5.61.2# 1.60.36 0.82 1.42 0.82
PMNs % 1.030.39 7.052.03# 1.210.14 1.65 0.68 1.38
104 cells.mL-1 0.100.02 0.910.19# 0.130.03 1.65 1.09 1.53
Eosinophils % 0.310.15 0.860.53 0.550.18 0.31 0.30 0.17
104 cells.mL-1 0.050.03 0.190.11# 0.030.05 0.30 0.42 0.49
CD4/CD8 ratio 4.41.2# 3.00.5 1.90.3 0.37 0.90 0.89
Data are presented as mean valuesSEM. Group 1: patients with an absolute number of polymorphonuclear neutrophils (PMNs) in BALF
#0.26104 cells.mL-1; group 2: patients with PMNs >0.26104 cells.mL-1; group 3: a healthy control group (all nonsmokers). AM:
alveolar macrophages. +: p<0.03 group 1 versus group 2; #: p<0.0001 versus group 3.
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The three other patients did not respond at all to the
initiated corticosteroid treatment. In two cases methotrex-
ate was started once a week orally, whilst in the third case
cyclophosphamide was considered. These three patients,
having the most severe sarcoidosis, all appeared to have an
absolute number of PMNs in BALF above 16104 cells.
mL-1. The final effect of the immunosuppressive agents
could not be evaluated.
Course of the disease of the studied sarcoidosis patients
With respect to the course of the disease, the sarcoidosis
patients were divided into three groups: those who recov-
ered spontaneously (group A; n=18), those who respond-
ed to corticosteroid treatment (group B; n=5) and those
who deteriorated (group C; n=3); (table 3). Only the ab-
solute number of PMNs in BALF differed significantly
between group C (Cohen's d 5.71) versus group A as well
as group B (Cohen's d 2.26). Almost all the patients in
groups A and B demonstrated an absolute PMN value
<0.926104 cells.mL-1. The only exception appeared to
have a PMN value of 1.406104 cells.mL-1. The patients
in group C had an absolute PMN value of $1.226104
cells.mL-1. The percentage PMNs differed between group
A and group C (Cohen's d 2.43). The FEV1 differed be-
tween group A versus group B (Cohen's d 2.10) and
group C (Cohen's d 3.43).The TL,CO differed between
group A versus group B (Cohen's d 1.47) and group C
(Cohen's d 2.83). The visual HRCT subscore thickening
or irregularity of the BVB differed between group A
versus group B (Cohen's d 1.78) and group C (Cohen's d
2.95). In contrast, no such differences were found in the
lymphocyte count or any other cell type present in BALF
nor in the presented extrapulmonary symptoms such as
erythema nodosum. When looking at the frequency con-
tribution of the radiographic stage of the three recovery
groups, it appeared that in group A three patients had
radiographic stage 0, five had stage I, eight had stage II,
and two had stage III. In group B, there were two patients
with stage II and two with stage III. Finally, of the patients
in group C one had stage II, one had stage III, and one had
stage IV (Chi-squared (8)=13.3, p=0.01).
Discussion
The present study showed that patients suffering from
sarcoidosis (with a more advanced, chronic disease course,
functional impairment, poor response to corticosteroid treat-
ment and persisting abnormal chest radiographs) demon-
strated a higher number of PMNs, but not a different
number of lymphocytes in BALF compared to those who
recovered spontaneously. These findings point out the
Table 2. ± A summary of the clinical characteristics of patients with sarcoidosis
Group 1 Group 2 Cohen's d
Laboratory characteristics
ESR (0±12) mm.h-1 13.93.7 13.33.2 0
sACE (9±25) U.L-1 25.52.0 26.82.0 0.41
Calcium (2.10±2.60) mmol.L-1 2.450.02 2.400.03 0
Uric acid (0.20±0.42) mmol.L-1 0.370.02 0.350.05 0
C-reactive protein (2±9) mg.mL-1 7.81.5 10.92.1 0.44
Lung function test results
FEV1 % pred 97.62.7# 68.66.1 1.11
FVC % pred 113.56.0# 81.56.1 1.16
TL,CO % pred 100.94.2# 67.87.3 1.09
PI,max (RV) cmH2O -95.46.8 -83.67.7 0.40
PE,max (TLC) cmH2O 108.010.0 96.28.6 0.26
Pa,O2 kPa 12.10.5* 10.30.5 0.88
Imaging procedures
Radiographic stage 0/I/II/III/IV n 3/5/7/0/0*** 0/0/4/6/1
67Ga scintigraphy scores yes/no n
Lymph nodes, mediastinal/hilar 8/7 5/6
Lung parenchyma 3/12*** 8/3
Extrathoracic localization 7/8 6/5
HRCT scores
Thickening or irregularity of BVB 0.250.13*** 1.900.41 1.77
Enlargement of LN 1.000.28* 1.800.25 0.45
Septal and nonseptal lines 0.250.13*** 1.300.33 1.02
Intraparenchymal nodules 0.330.26# 2.200.33 1.34
Parenchymal consolidation 0.500.26* 1.300.26 0.68
Total score 2.500.45# 8.500.93 1.69
Follow-up
Spontaneous remission yes/no n 14/1*** 4/7
Data are presented as meanSEM. Reference ranges of laboratory values are shown in parentheses. Group 1: patients with an absolute
number of polymorphonuclear neutrophils (PMNs) in bronchoalveolar lavage fluid #0.26104 cells.mL-1; group 2: patients with PMNs
>0.26104 cells.mL-1 (all nonsmokers). ESR: erythrocyte sedimentation rate; sACE: serum angiotension converting enzyme; FEV1:
forced expiratory volume in one second; FVC: forced vital capacity; TL,CO: transfer factor of the lung for carbon monoxide; PI,max
(RV): maximal inspiratory mouth pressure at residual volume; PE,max (TLC): maximal expiratory mouth pressure at total lung capacity;
Pa,O2: arterial oxygen tension; HRCT: high-resolution computed tomography; BVB: bronchovascular bundle; LN: lymph nodes. *:
p<0.05; ***p<0.001; #: p<0.0001, group 1 versus group 2.
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potential practical value of cellular BALF analysis in pa-
tients suffering from sarcoidosis in assessing the prognosis
of their disease, in addition to the diagnostic value.
There is considerable incongruity among the clinical,
radiographic, physiological and immunological findings
used in predicting the course and prognosis of the granu-
lomatous process in sarcoidosis [1, 14, 16±19]. The
intensity of the alveolitis was thought to correlate with the
course of the disease [20]. Many patients with an acute
onset and good prognosis were found to have a lym-
phocytosis and high CD4/CD8 ratio in the BALF. Similar
to other studies [21, 22], this and previous studies [4, 5]
demonstrated a similar discordance between the intensity
of the inflammatory process, indicated by lymphocytosis,
and the course of the disease. In contrast, a negative re-
lationship between the pretreatment absolute number of
PMNs in BALF and remission of the disease was found.
It is realized that the results of this study should be
interpreted with caution due to the rather limited sample
size of the studied sarcoidosis patient population. How-
ever, the results are in agreement with the findings of
ROTH et al. [23] and LIN et al. [24] who also demonstrated
that abnormal neutrophil counts in BALF were associated
with a poor prognosis in sarcoidosis.
Mostly, in IPF or cryptogenic fibrosing alveolitis (CFA)
and in collagen vascular diseases, a lymphocytosis in
BALF indicated a moderate-to-severe alveolar inflamma-
tion and a good response to treatment with corticosteroids
[7, 8]. In contrast, a neutrophilic and eosinophilic alv-
eolitis was associated with a poor clinical response. As in
many other diffuse interstitial lung disorders a great deal
of uncertainty remains about the appropriate way to treat
sarcoidosis, compounded by the lack of knowledge of
how to predict the natural course of the untreated disease
[1, 24, 25]. In most cases, pulmonary involvement sta-
bilizes or clears in >80% of affected patients. In the
present study, all but one (85.7%) of the cases of group 1
with a normal number of PMNs in BALF demonstrated
clinical improvement at the six months assessment, sug-
gesting that the degree of illness was reversible. BAUGH-
MAN et al. [26] demonstrated that patients who die from
respiratory failure due to their sarcoidosis had fibrosis
shown on chest radiography and a reduced vital capacity,
usually <1.5 L. In the present study, the radiographic
stage as well as the visual HRCT score were found to be
related with the course of the disease. Moreover, the three
patients for whom lung transplantation was considered,
demonstrated more or less severe fibrotic signs and high
numbers of PMNs in BALF.
sACE levels and other markers of cell activation sar-
coidosis [2, 19] as well as 67Ga scans in general have a
poor predictive value [25, 27]. In the present study, no
difference was found between the two sarcoidosis sub-
groups and clinical recovery with respect to the sACE
level. Similar to others [17±19], this study did not find
that the 67Ga scintigraphy, findings were superior to the
HRCT findings, but appeared to be useful to assess extra-
thoracic localizations of sarcoidosis [14]. Moreover, this
study, in agreement with REMY-JARDIN et al. [28], found a
correlation of the HRCT appearance with the FEV1,
TL,CO, PI,max as well as the absolute number of PMNs in
BALF, whereas the 67Ga uptake only appeared to be re-
lated to the FEV1 (data not shown). With respect to lung
function, it was found that cases with a high number of
PMNs in BALF demonstrated significantly more im-
pairment compared to sarcoidosis patients with a normal
absolute number of PMNs in BALF. KARETZKY and
MCDONOUGH [29] demonstrated that the magnitude of
functional impairment varied widely from apparent his-
topathological involvement as reflected by a chest radio-
graph and lung volumes. They found a wide spectrum of
tissue inflammation and organ dysfunction between and
Table 3. ± Summary of the clinical characteristics of sarcoidosis patients with respect to the course of the disease
Group A Group B Group C
Cohen's d
n=18 n=5 n=3 Group A vs B Group A vs C Group B vs C
Laboratory characteristics
sACE (9±25) U.L-1 26.51.86 25.82.06 24.02.89 0.10 0.33 0.32
C-reactive protein (2±9) mg.mL-1 8.861.61 8.334.10 10.672.40 0.09 0.32 0.40
Lung function test results
FEV1 % pred 96.32.4 67.010.3** 59.77.8** 2.10 3.43 0.12
TL,CO % pred 98.24.5 70.87.5** 45.78.5** 1.47 2.83 1.57
PI,max (RV) cmH2O -97.16.0 -78.77.5 -67.37.0 1.81 1.31 0.90
Imaging procedures HRCT scores
BVB 0.400.21 2.000.58** 2.680.33** 1.78 2.95 1.68
LN 1.400.25 0.750.48 2.010.00 0.65 0.66 1.65
LS 0.530.19 1.020.58 1.330.88 0.57 0.90 0.25
ND 1.030.35 1.250.75 2.020.58 0.18 0.75 0.57
PC 0.530.22 1.750.48 1.330.33 1.44 1.04 0.49
Total score 4.020.88 6.801.59 9.280.88 0.81 1.68 0.85
BALF analysis results
Lymphocytes % 40.44.98 19.74.16 40.212.94 1.08 0.01 1.32
104 cell.mL-1 7.771.61 3.411.27 8.394.02 0.71 0.09 1.03
PMNs % 1.580.47 5.422.18 12.406.18** 1.33 2.43 0.92
104 cells.mL-1 0.200.05 0.580.24# 1.710.32** 1.30 5.71 2.26
Data are presented as meanSEM. Reference ranges of laboratory values in parentheses. Group A: patients who recovered sponta-
neously; group B: patients who responded to corticosteroid treatment; group C: those patients who deteriorated. LS: septal and
nonseptal lines; ND: intraparenchymal nodules; PC: parenchymal consolidation; BALF: bronchoalveolar lavage fluid; PMNs:
polymorphonuclear neutrophils. For other definitions see footnote to table 2. **: p<0.001 versus group A; #: p<0.001 versus group C.
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within each radiographic stage. Moreover, their results
indicated that a routine chest radiograph provides a very
limited estimate of function for any given individual and
that a TL,CO of <55% was the most sensitive indicator at
rest for exercise limitation. In the present study, the FEV1
and TL,CO allowed a distinction between patients who
recovered spontaneously and those patients who needed
treatment and/or deteriorated. The radiographic stage did
not seem to be a potential predictor of disease progres-
sion. However, the absolute number of PMNs appeared to
be a better potential predictor because this parameter
differed significantly between those patients who recover-
ed spontaneously (group A) and those who needed treat-
ment (group B), and in addition, between group B and
those who deteriorated (group C).
Sarcoidosis is often acute and self-limiting, but may also
have a chronic pattern, waxing and waning over a long
period [1]. It is tempting to speculate that the neutrophil
component of the inflammation, including mediators such
as collagenase [30], toxic oxidant radicals and proteases,
also has the potential to contribute to alveolar wall in-
jury in sarcoidosis [23, 24]. In this context, although more
data supporting the importance of the neutrophil in the
pathogenesis of sarcoidosis are really needed, it is rea-
sonable to suggest that suppression of the neutrophil
component of the inflammation of sarcoidosis should also
be considered in the treatment decisions. CAR et al. [31]
demonstrated significantly elevated interleukin-8 levels
in BALF of sarcoidosis patients and IPF patients. For
interleukin-8 a role has been suggested in the attraction of
neutrophils to inflamed tissues.
In conclusion, an increase of the polymorphonuclear
neutrophil count in bronchoalveolar lavage fluid obtained
from sarcoidosis patients appeared to be associated with
more advanced disease. This result highlights that poly-
morphonuclear neutrophils, but not lymphocytes, may play
a crucial role in the outcome of sarcoidosis and evolution
of the inflammatory process toward pulmonary fibrosis.
Therefore, cellular bronchoalveolar lavage fluid analysis
may be of additional practical value in predicting the
course of the disease in an individual patient. However, the
exact role of polymorphonuclear neutrophils in the pa-
thogenesis and prognosis of patients suffering from sar-
coidosis needs further investigation to elucidate the many
remaining questions, especially whether they could be
therapeutic targets.
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